C Mulatero

2.5k total citations
37 papers, 988 citations indexed

About

C Mulatero is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, C Mulatero has authored 37 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in C Mulatero's work include Immunotherapy and Immune Responses (9 papers), Lung Cancer Research Studies (7 papers) and CAR-T cell therapy research (6 papers). C Mulatero is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Lung Cancer Research Studies (7 papers) and CAR-T cell therapy research (6 papers). C Mulatero collaborates with scholars based in United Kingdom, United States and Australia. C Mulatero's co-authors include Michael Thomas, Jacqui Rowbottom, Patrapim Sunpaweravong, Glenwood Goss, Sumitra Thongprasert, Sven Gogov, David Ferry, Joyce Thompson, Fabrice Barlési and Ronald B. Natale and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

C Mulatero

36 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C Mulatero United Kingdom 18 660 375 240 158 108 37 988
Samuel S. Dychter United States 14 544 0.8× 268 0.7× 256 1.1× 180 1.1× 142 1.3× 25 1.2k
Mustafa Erman Türkiye 18 401 0.6× 271 0.7× 124 0.5× 118 0.7× 56 0.5× 117 1.0k
Petra Rietschel United States 12 365 0.6× 196 0.5× 189 0.8× 117 0.7× 135 1.3× 54 1.5k
Karen Keating United States 19 405 0.6× 196 0.5× 291 1.2× 262 1.7× 144 1.3× 60 1.1k
Jessica R. Bauman United States 18 802 1.2× 392 1.0× 124 0.5× 215 1.4× 155 1.4× 106 1.3k
Wolfgang Lamm Austria 20 494 0.7× 333 0.9× 303 1.3× 100 0.6× 59 0.5× 76 1.0k
V. Gounant France 23 831 1.3× 960 2.6× 267 1.1× 167 1.1× 92 0.9× 133 1.6k
Ann Setser United States 9 456 0.7× 250 0.7× 167 0.7× 118 0.7× 129 1.2× 11 1.0k
C. Kortsik Germany 19 539 0.8× 712 1.9× 258 1.1× 133 0.8× 252 2.3× 59 1.4k
Amy Rapkiewicz United States 15 266 0.4× 229 0.6× 200 0.8× 143 0.9× 113 1.0× 48 1.3k

Countries citing papers authored by C Mulatero

Since Specialization
Citations

This map shows the geographic impact of C Mulatero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Mulatero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Mulatero more than expected).

Fields of papers citing papers by C Mulatero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Mulatero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Mulatero. The network helps show where C Mulatero may publish in the future.

Co-authorship network of co-authors of C Mulatero

This figure shows the co-authorship network connecting the top 25 collaborators of C Mulatero. A scholar is included among the top collaborators of C Mulatero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Mulatero. C Mulatero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woll, Penella J., Piers Gaunt, Sarah Danson, et al.. (2022). Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 171. 26–33. 30 indexed citations
2.
Woll, Penella J., Piers Gaunt, Nicola Steele, et al.. (2017). P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC. Journal of Thoracic Oncology. 12(1). S704–S705. 17 indexed citations
3.
Popat, Sanjay, Laura Hughes, Mary O’Brien, et al.. (2017). P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial). Journal of Thoracic Oncology. 12(1). S1215–S1216. 3 indexed citations
4.
Arriola, Edurne, Matthew Wheater, Ian Galea, et al.. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(9). 1511–1521. 97 indexed citations
5.
Middleton, Mark R., Pippa Corrie, Mario Sznol, et al.. (2015). A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 75. 3 indexed citations
6.
Califano, Raffaele, Scott N. Compton, D. A. Fitzgerald, et al.. (2015). Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 75(12). 1335–1348. 95 indexed citations
7.
Patel, Poulam M., Christian H. Ottensmeier, C Mulatero, et al.. (2015). An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients.. Journal of Clinical Oncology. 33(15_suppl). 9035–9035. 1 indexed citations
8.
9.
Middleton, Mark R., JEFF EVANS, Neil Steven, et al.. (2014). A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 74. 1 indexed citations
10.
Molassiotis, Alex, Lisa Brunton, Jackie Hodgetts, et al.. (2014). Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Annals of Oncology. 25(10). 2052–2058. 51 indexed citations
11.
Middleton, Mark R., Jason V. Evans, Neil Steven, et al.. (2013). IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.. Cancer Research. 73. 2 indexed citations
12.
Besse, Benjamin, Rebecca S. Heist, D. Ross Camidge, et al.. (2013). A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Annals of Oncology. 25(2). 505–511. 20 indexed citations
13.
Ford, John, Rob Jones, Andrew Elders, et al.. (2012). Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis. European Journal of Cancer. 49(2). 416–430. 44 indexed citations
14.
15.
Natale, Ronald B., Sumitra Thongprasert, F. Anthony Greco, et al.. (2011). Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(8). 1059–1066. 244 indexed citations
16.
Jayson, Gordon C., C Mulatero, Malcolm Ranson, et al.. (2005). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. European Journal of Cancer. 41(4). 555–563. 36 indexed citations
17.
Mulatero, C, et al.. (2001). A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 31(1). 67–72. 26 indexed citations
18.
Jayson, Gordon C., Jamal Zweit, C Mulatero, et al.. (2001). PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study. European Journal of Cancer. 37. S101–S101. 1 indexed citations
19.
20.
Mulatero, C, et al.. (1999). Simian virus 40 and human pleural mesothelioma. Thorax. 54(1). 60–61. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel S. Dychter Breakdown of academic impact, for papers by Mustafa Erman Breakdown of academic impact, for papers by Petra Rietschel Breakdown of academic impact, for papers by Karen Keating Breakdown of academic impact, for papers by Jessica R. Bauman Breakdown of academic impact, for papers by Wolfgang Lamm Breakdown of academic impact, for papers by V. Gounant Breakdown of academic impact, for papers by Ann Setser Breakdown of academic impact, for papers by C. Kortsik Breakdown of academic impact, for papers by Amy Rapkiewicz
Rankless by CCL
2026